Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Differentiated Thyroid Cancer × Injections × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Leukemia, Myeloid, Acute 21 Breast Neoplasms 14 Myelodysplastic Syndromes 9 Stomach Neoplasms 8 Leukemia, Myelomonocytic, Chronic 7 Sarcoma 6 Myeloproliferative Disorders 6 Multiple Myeloma 6 Lymphoma, Large B-Cell, Diffuse 5 Carcinoma, Non-Small-Cell Lung 5 Uterine Cervical Neoplasms 4 Recurrence 4 Neoplasms 4 Melanoma 4 Leukemia, Monocytic, Acute 4 Head and Neck Neoplasms 4 Carcinoma, Hepatocellular 4 Biliary Tract Neoplasms 4 Advanced Solid Tumour 4 Stomatitis 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neuroendocrine Tumors 3 Mucositis 3 Lung Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Transitional Cell 3 Neoplasm Metastasis 2 Mouth Neoplasms 2 Lymphoma, T-Cell, Peripheral 2

Interventions

surufatinib 1 pembrolizumab 1 lenvatinib 1 donafenib 1 Thyrotropin Alfa 1 Sorafenib 1 Injections 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡